As such, SGLT2 inhibitors and GLP-1R agonists to an extent, have been shown to reduce cardiovascular events in people with T2DM, while also reducing hospitalization rates for heart failure. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.